SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) January 13, 2004
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | | 94-3267443 |
| (Commission file Number) | | (IRS Employer ID Number) |
| 8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
On January 13, 2004, Salix Pharmaceuticals, Ltd. issued a press release announcing that Azasan® (azathioprine tablets), its recently acquired product, has been shipped to wholesale distributors and will be available to patients beginning within a few weeks. A copy of this press release is attached.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No.
| | Description
|
| 99.1 | | Press release dated January 13, 2004 of Salix Pharmaceuticals, Ltd., announcing that Azasan® (azathioprine tablets), its recently acquired product, has been shipped to wholesale distributors and will be available to patients beginning within a few weeks. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | SALIX PHARMACEUTICALS, LTD. |
| | | |
| Date: January 13, 2004 | | | | By: | | /s/ Adam C. Derbyshire
|
| | | | | | | | | Adam C. Derbyshire Senior Vice President and Chief Financial Officer |
